Rekombinanter CTLA4 Antikörper

Produktnummer ABIN7072438

Dieser Hamster Monoklonal Antikörper detektiert spezifisch CTLA4 in WB, FACS, ELISA, Neut und ProA. Es zeigt Reaktivität gegenüber Proben von Maus.

Kurzübersicht für Rekombinanter CTLA4 Antikörper (ABIN7072438)

Target: CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))

Antikörpertyp: Recombinant Antibody

Reaktivität: Maus

Wirt: Hamster

Klonalität: Monoklonal

Konjugat: Dieser CTLA4 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Flow Cytometry (FACS), ELISA, Neutralization (Neut), Proliferation Assay (ProA)

Klon: 9H10

Produktdetails anti-CTLA4 Antikörper

Verwendungszweck: Anti-CTLA-4 [9H10], Hamster (Armenian) IgG, kappa

Spezifität: This antibody is specific for murine CTLA-4, an inhibitory receptor that acts as the primary negative regulator of T-cell responses. CTLA-4 is expressed predominantly by activated T cells, with significantly higher levels of expression on CD8+ T cells than CD4+ T cells.

Produktmerkmale:

Original Species of Ab: Hamster, Armenian

Original Format of Ab: IgG2

Aufreinigung: Protein A affinity purified

Immunogen: This antibody was raised by immunising Syrian hamsters with Staphylococcus A bacteria coated in CTLA-4, isolating B cells from the immunised hamsters and fusing these with the P3X3.Ag8.653 myeloma line to produce stable hybridomas.

Isotyp: IgG kappa

Anwendungsinformationen

Applikationshinweise: CTLA-4 is upregulated on T cells following their activation, and acts as a negative regulator of T cell responses, CTLA-4 binds to the B7 Molecules CD80 and 86, resulting in the delivery of an inhibitory signal, and consequent downregulation of T cell-mediated immunity. Administration of 9H10 blocks the interaction between CTLA-4 on the T cell surface and CD80 and CD86. This promotes the activation of effector T cells and stimulates the immune response raised against weak antigens, including tumour antigens. While this antibody alone does not enhance T cell proliferation, it does significantly increase T cell proliferation when administered together with anti-CD28 (clone 37.51) (Krummel & Allison, 1995), anti-OX40 and anti-GITR (Houot & Levy, 2009). Blocking CTLA-4 induces T cell anti-tumour immunity in animal models, both by suppressing regulatory T cell activity and directly promoting CD8+ T cell effector function (Peggs et al, 2009). In transgenic murine models of prostate cancer, the use of a CTLA-4 blockade in conjunction with an irradiated tumour cell vaccine stimulates an immune response against primary tumours, and results in a significant reduction in tumour incidence (Hurwitz et al, 2000). Similarly, in murine melanoma models, CTLA-4 blockage, in combination with CD40 stimulation and adenoviral vaccination, can elicit complete regression (Sorensen et al, 2010). In murine models of pancreatic ductal adenocarcinoma, 9H10 has also been shown to induce T cell-dependent tumour regressions (Vonderheide et al, 2015). Priming the T cell response with CD40 mAbs or chemotherapy reversed the resistance to 9H10 and RMP1-14 observed in well-established tumours. Additionally, this antibody has been used to detect CTLA-4 using ELISA (Krummel & Allison, 1995) and to stain CTLA-4-expressing cells (Deeths et al, 1999).

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Details zu CTLA4

Target: CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))

Andere Bezeichnung: CTLA-4

Hintergrund: CD152, CTLA4, cytotoxic T-lymphocyte-associated antigen 4, Cytotoxic T-lymphocyte protein 4,

UniProt: P09793

Pathways: Cancer Immune Checkpoints